Abstract Treatment outcomes for major depressive disorder (MDD) need to be improved.
Presently, no clinically relevant tools have been established for stratifying subgroups or …

The underlying neurobiological basis of major depressive disorder remains elusive due to
the severity, complexity, and heterogeneity of the disorder. While the traditional …

Clinical and preclinical studies suggest that dysfunction of the glutamatergic system is
implicated in mood disorders such as major depressive disorder and bipolar depression. In …

Human studies suggest that a variety of prenatal stressors are related to high risk for cognitive
and behavioral abnormalities associated with psychiatric illness (Markham and Koenig, …

Allopregnanolone (ALLO), synthesized by pyramidal neurons, is a potent positive allosteric
modulator of the action of GABA at GABA A receptors expressing specific neurosteroid …

In the cerebral prefrontal cortex (PFC), DNA-methyltransferase 1 (DNMT1), the enzyme that
catalyzes the methylation of cytosine at carbon atoms in position 5 in CpG dinucleotides, is …

Ketamine improves motivation-related symptoms in depression but simultaneously elicits
similar symptoms in healthy individuals, suggesting that it might have different effects in health …

… Additional funding was provided by NARSAD Young Investigator Award to Dr Kadriu.
The NIMH and NARSAD had no further role in study design; in the collection, analysis or …

The discovery of ketamine as a rapid-acting antidepressant spurred significant research to
understand its underlying mechanisms of action and to identify other novel compounds that …

Background The glutamatergic modulator ketamine has created a blueprint for studying
novel pharmaceuticals in the field. Recent studies suggest that “classic” serotonergic …